NCT01654367

Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer

The Effectiveness and Safety of Treating Operable Breast Cancer by the Adjuvant Therapy of Zoledronic Acid and Aromatase Inhibitors and/or Ovarian Function Inhibition

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Tianjin Medical University · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

Select patients of primary breast cancer whose hormone receptor is positive and accepted postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with zoledronic acid 4mg intravenous infusion every six months until the end of the aromatase treatment. Assess the disease-free survival; overall survival; combination of security, as well as the situation of bone loss.

Detailed description

The investigators select patients of primary breast cancer whose hormone receptor is positive and accepted postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with zoledronic acid 4mg intravenous infusion every six months until the end of the aromatase treatment. Assess the disease-free survival; overall survival; combination of security, as well as the situation of bone loss.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Zoledronic Acid and Aromatase Inhibitors	Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy

Timeline

• Start date: 2012-01-01
• Primary completion: 2012-12-01
• Completion: 2013-12-01
• First posted: 2012-07-31
• Last updated: 2012-07-31

Locations

1 site across 1 country: China